An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer
NCT ID: NCT01461044
Last Updated: 2016-01-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
228 participants
OBSERVATIONAL
2011-09-30
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
NCT00717405
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
NCT00559845
An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer
NCT01661153
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
NCT00528567
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line
NCT03462251
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HER2-metastatic breast cancer or locally advanced breast cancer
* Patients with Avastin as first line therapy administered for at least 12 months
* Patients without disease progression after the beginning of Avastin treatment for at least 12 months
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aix-en-Provence, , France
Aix-en-Provence, , France
Ajaccio, , France
Amiens, , France
Antony, , France
Arras, , France
Bastia, , France
Bayonne, , France
Beauvais, , France
Besançon, , France
Béziers, , France
Bobigny, , France
Bordeaux, , France
Bordeaux, , France
Boulogne-Billancourt, , France
Bourg-en-Bresse, , France
Brest, , France
Caen, , France
Chambéry, , France
Châteauroux, , France
Cherbourg Octeville, , France
Clermont-Ferrand, , France
Clermont-Ferrand, , France
Créteil, , France
Dax, , France
Dijon, , France
Eaubonne, , France
Évreux, , France
Grenoble, , France
La Chaussée-Saint-Victor, , France
La Roche-sur-Yon, , France
La Tronche, , France
Le Coudray, , France
Lille, , France
Lille, , France
Limoges, , France
Longjumeau, , France
Lorient, , France
Lormont, , France
Lyon, , France
Lyon, , France
Marseille, , France
Marseille, , France
Marseille, , France
Metz, , France
Montivilliers, , France
Mougins, , France
Nancy, , France
Narbonne, , France
Nice, , France
Osny, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Périgueux, , France
Reims, , France
Romans-sur-Isère, , France
Rouen, , France
Rouen, , France
Saint-Brieuc, , France
Saint-Cloud, , France
Saint-Germain-en-Laye, , France
Saint-Grégoire, , France
Saint-Jean, , France
Saint-Michel-sur-Orge, , France
Saint-Priest-en-Jarez, , France
Senlis, , France
Soyaux, , France
Strasbourg, , France
Toulon, , France
Toulouse, , France
Toulouse, , France
Troyes, , France
Valence, , France
Vannes, , France
Verdun, , France
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML27760
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.